HomeCompareBBI vs YUM

BBI vs YUM: Dividend Comparison 2026

BBI yields 85.11% · YUM yields 1.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BBI wins by $1.97M in total portfolio value
10 years
BBI
BBI
● Live price
85.11%
Share price
$2.35
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.08M
Annual income
$627,483.66
Full BBI calculator →
YUM
YUM
● Live price
1.86%
Share price
$154.59
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.9K
Annual income
$40,443.52
Full YUM calculator →

Portfolio growth — BBI vs YUM

📍 BBI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBBIYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BBI + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BBI pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BBI
Annual income on $10K today (after 15% tax)
$7,234.04/yr
After 10yr DRIP, annual income (after tax)
$533,361.11/yr
YUM
Annual income on $10K today (after 15% tax)
$158.35/yr
After 10yr DRIP, annual income (after tax)
$34,376.99/yr
At 15% tax rate, BBI beats the other by $498,984.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BBI + YUM for your $10,000?

BBI: 50%YUM: 50%
100% YUM50/50100% BBI
Portfolio after 10yr
$1.09M
Annual income
$333,963.59/yr
Blended yield
30.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

BBI
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
-7.2
Piotroski
4/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+12.0% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BBI buys
0
YUM buys
0
No recent congressional trades found for BBI or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBBIYUM
Forward yield85.11%1.86%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$2.08M$107.9K
Annual income after 10y$627,483.66$40,443.52
Total dividends collected$1.82M$81.2K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyHold

Year-by-year: BBI vs YUM ($10,000, DRIP)

YearBBI PortfolioBBI Income/yrYUM PortfolioYUM Income/yrGap
1← crossover$19,211$8,510.64$10,982$282.06+$8.2KBBI
2$35,835$15,279.89$12,189$438.29+$23.6KBBI
3$64,982$26,638.22$13,731$688.32+$51.3KBBI
4$114,675$45,144.37$15,789$1,097.12+$98.9KBBI
5$197,158$74,455.37$18,679$1,785.08+$178.5KBBI
6$330,593$119,634.65$22,975$2,988.18+$307.6KBBI
7$541,214$187,479.44$29,784$5,200.49+$511.4KBBI
8$865,943$286,843.50$41,408$9,539.16+$824.5KBBI
9$1,355,484$428,924.80$63,071$18,765.27+$1.29MBBI
10$2,077,851$627,483.66$107,930$40,443.52+$1.97MBBI

BBI vs YUM: Complete Analysis 2026

BBIStock

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Full BBI Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this BBI vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BBI vs SCHDBBI vs JEPIBBI vs OBBI vs KOBBI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.